Mesoblast Ltd (MSB)

0.990
-0.015(-1.49%)
  • Volume:
    927,685
  • Bid/Ask:
    0.990/0.995
  • Day's Range:
    0.985 - 1.010

MSB Overview

Prev. Close
1.005
Day's Range
0.985-1.01
Revenue
13.62M
Open
1.005
52 wk Range
0.965-2.34
EPS
-0.22
Volume
927,685
Market Cap
643.41M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
1,659,365
P/E Ratio
-
Beta
2.91
1-Year Change
-47.34%
Shares Outstanding
649,911,648
Next Earnings Date
29 Aug 2022
What is your sentiment on Mesoblast?
or
Market is currently closed. Voting is open during market hours.

Mesoblast Ltd News

  • ASX Trades Higher as Tech Recovers
    • ByInvesting.com-

    By Oliver Gray Investing.com - The ASX 200 was 67.60 points or 0.91% higher at 7,457.70 in Wednesday’s mid-morning deals, with market participants tracking an overnight rally on...

  • Australian Shares Finish Flat, Mesoblast Falls 17%
    • ByInvesting.com-

    By Oliver GrayInvesting.com - The S&P/ASX 200 finished Tuesday's session just 0.01% lower at 7378.4 after gains of 0.3% in the previous session, with the consumer staples sector...

Mesoblast Ltd Analysis

Mesoblast Ltd Company Profile

Mesoblast Ltd Company Profile

Employees
83
Market
Australia

Mesoblast Limited is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company is using its mesenchymal lineage cell technology platform to develop and commercialize allogeneic cellular medicines to treat complex inflammatory diseases. Its product candidate includes Remestemcel-L ((RYONCIL) for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), Rexlemestrocel-L (REVASCOR) for the advanced chronic heart failure (CHF) and MPC-06-ID for the treatment of chronic low back pain caused by disc degeneration (CLBP). Its product candidate MPC-150-IM for the treatment or prevention of chronic heart failure and MPC-25-IC for the treatment or prevention of acute myocardial infarction. Its product candidate also includes MPC-300-IV for the treatment of biologic-refractory rheumatoid arthritis and diabetic nephropathy.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellSellStrong SellStrong Sell
Technical IndicatorsSellSellStrong SellStrong SellStrong Sell
SummarySellSellStrong SellStrong SellStrong Sell
  • i don't understand anything here
    0
    • am new an in I don't understand anything here
      0
      • just buy
        2
        • what is the update for MSB? Buy, Hold or Sell?
          0
          • what is the update for MSB? Buy, Hold or Sell?
            0
            • Watch the sellout tomorrow
              0
              • in my opinion msb will recover quite quickly from current share price. its a lot happening in US including th election. I would be worry if this is the only product they have inline but they have other products which are currently in stage 3 and some will soon be going for fda approval." be greedy when others are fearful " warren buffett
                4
                • It has been a on indicative sell for the lst few weeksAfter that hitThe indicators and MA will promote a further sellThere may be bullish rally due to the fact of how cheap it is since it hasnt dropped this low since 2016But that wont last long as there will be drastic pullback till they prove the product and build investor confident back up
                  1
              • in my opinion msb will recover quite quickly from current share price. its a lot happening in US including th election. I would be worry if this is the only product they have inline but they have other products which are currently in stage 3 and some will soon be going for fda approval." be greedy when others are fearful " warren buffett
                2
                • Buy or Sell?
                  2
                  • if you think they have more ammo in the bank to prove themselves to the FDA - it's shopping time!
                    0
                  • Definitely sell, the sentiment is bearish. The share price will not bounce in the foreseeable future unless treatment efficacy is further substantiated & FDA approval is granted. There is a long way to go before this happens.
                    0
                  • George SalmaStotally agree, thats what i said. Absolute gamble if you buy, youre more likely to win against the casino than to make money on this share. A buy would be around the march low, $1 something
                    0
                • overpriced in my opinion
                  4
                  • based on what just happened. it dropped due to FDA not being in favour. time to buy very soon. price drop for some yum yum
                    0
                  • based on what just happened. it dropped due to FDA not being in favour. time to buy very soon. price drop for some yum yum
                    0
                  • tu nguyena buy at its march low is a buy for a quick buck
                    0